[1] |
Howlader N, Noone AM, Krapcho M, et al. Age-adjusted and age-specific SEER cancer incidence rates review, 1975-2014, National Cancer Institute. Bethesda[DB/OL]. (2018-04-02) [2019-03-02].
URL
|
[2] |
Litten JB, Tomlinson GE. Liver tumors in children[J]. Oncologist, 2008, 13(7): 812-820.
|
[3] |
Allan BJ, Parikh PP, Diaz S, et al. Predictors of survival and incidence of hepatoblastoma in the paediatric population[J]. HPB (Oxford), 2013, 15(10): 741-746.
|
[4] |
Hung GY, Lin LY, Yu TY, et al. Hepatoblastoma incidence in Taiwan: a population-based study[J]. J Chin Med Assoc, 2018, 81(6): 541-547.
|
[5] |
Ikeda H, Nakamura Y. Trends in incidence of childhood malignant solid tumors in Japan: estimation based on hospital-based registration[J]. J Pediatr Surg, 2015, 50(9): 1506-1512.
|
[6] |
Exelby PR, Filler RM, Grosfeld JL. Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey--1974[J]. J Pediatr Surg, 1975, 10(3): 329-337.
|
[7] |
de Camargo B, de Oliveira Ferreira JM, de Souza Reis R, et al. Socioeconomic status and the incidence of non-central nervous system childhood embryonic tumours in Brazil[J]. BMC Cancer, 2011, 11: 160.
|
[8] |
Towbin AJ, Meyers RL, Woodley H, et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT)[J]. Pediatr Radiol, 2018, 48(4): 536-554.
|
[9] |
Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group[J]. Pediatr Radiol, 2007, 37(2): 123-132; quiz 249-250.
|
[10] |
中国抗癌协会小儿肿瘤专业委员会,中华医学会小儿外科分会肿瘤专业组. 儿童肝母细胞瘤多学科诊疗专家共识(CCCG-HB-2016)[J]. 中华小儿外科杂志,2017, 38(10): 733-739.
|
[11] |
Czauderna P, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy[J]. Curr Opin Pediatr, 2014, 26(1): 19-28.
|
[12] |
Kumar SV, Lupo PJ, Pompeii LA, et al. Maternal residential proximity to major roadways and pediatric embryonal tumors in offspring[J]. Int J Environ Res Public Health, 2018, 15(3): E505.
|
[13] |
Turcotte LM, Georgieff MK, Ross JA, et al. Neonatal medical exposures and characteristics of low birth weight hepatoblastoma cases: a report from the Children′s Oncology Group[J]. Pediatr Blood Cancer, 2014, 61(11): 2018-2023.
|
[14] |
Czauderna P, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy[J]. Curr Opin Pediatr, 2014, 26(1): 19-28.
|
[15] |
Zsiros J, Brugieres L, Brock P, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study[J]. Lancet Oncol, 2013, 14(9): 834-842.
|
[16] |
Hiyama E, Hishiki T, Watanabe K, et al. Resectability and tumor response after preoperative chemotherapy in hepatoblastoma treated by the Japanese Study Group for Pediatric Liver Tumor (JPLT)-2 protocol[J]. J Pediatr Surg, 2016, 51(12): 2053-2057.
|
[17] |
Kremer N, Walther AE, Tiao GM. Management of hepatoblastoma: an update[J]. Curr Opin Pediatr, 2014, 26(3): 362-369.
|
[18] |
Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma, final report of the second study of the International Society of Paediatric Oncology: SIOPEL 2[J]. Eur J Cancer, 2004, 40(3): 411-421.
|
[19] |
Meyers RL, Maibach R, Hiyama E, et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children′s Hepatic tumors International Collaboration[J]. Lancet Oncol, 2017, 18(1): 122-131.
|
[20] |
Qiao GL, Li L, Cheng W, et al. Predictors of survival after resection of children with hepatoblastoma: a single Asian center experience[J]. Eur J Surg Oncol, 2014, 40(11): 1533-1539.
|
[21] |
张伟令,张谊,黄东生,等. 102例儿童肝母细胞瘤的治疗及预后分析[J]. 中国小儿血液与肿瘤杂志,2015, 20(6): 289-292.
|
[22] |
王天怡,潘慈,汤静燕,等. 儿童肝母细胞瘤74例随访研究[J]. 中华儿科杂志,2017, 55(5): 364-368.
|
[23] |
姚东亚,罗源,盛光耀. 儿童肝母细胞瘤36例预后分析[J]. 临床儿科杂志,2017, 35(2): 121-124.
|
[24] |
陆正华,杨静薇,邵静波,等. 小儿肝母细胞瘤24例的临床特点及预后因素分析[J]. 中国小儿血液与肿瘤杂志,2015, 20(2): 79-82.
|
[25] |
汤梦婕,袁晓军,谈珍,等. 多学科综合治疗47例儿童肝母细胞瘤的疗效评估[J]. 中华实用儿科临床杂志,2016, 31(15): 1175-1179.
|
[26] |
易优,张谊,张伟令,等. 晚期儿童肝母细胞瘤的预后分析[J]. 中国小儿血液与肿瘤杂志,2014, 19(6): 303-307.
|
[27] |
Shi Y, Commander SJ, Masand PM, et al. Vascular invasion is a prognostic indicator in hepatoblastoma[J]. J Pediatr Surg, 2017, 52(6): 956-961.
|
[28] |
Erginel B, Gun Soysal F, Keskin E, et al. Pulmonary metastasectomy in pediatric patients[J]. World J Surg Oncol, 2016, 14(1): 27.
|
[29] |
Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
|
[30] |
O′Neill AF, Towbin AJ, Krailo MD, et al. Characterization of pulmonary metastases in children with hepatoblastoma treated on children′s oncology group protocol AHEP0731 (the treatment of children with all stages of hepatoblastoma): a report from the children′s oncology group[J]. J Clin Oncol, 2017, 35(30): 3465-3473.
|
[31] |
Koh KN, Park M, Kim BE, et al. Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma[J]. Pediatr Blood Cancer, 2011, 57(4): 554-560.
|
[32] |
De Ioris M, Brugieres L, Zimmermann A, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience[J]. Eur J Cancer, 2008, 44(4): 545-550.
|